Rationale and Design of a Clinical Trial of Adapted Tango to Improve Negative Health Impacts in Middle Aged African-American Female Caregivers of Persons with Alzheimer’s Disease (ACT Trial)

2019 ◽  
Vol 68 (2) ◽  
pp. 767-775 ◽  
Author(s):  
Madeleine E. Hackney ◽  
Lauren E. McCullough ◽  
Allison A. Bay ◽  
Hayley A. Silverstein ◽  
Ariel R. Hart ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
African American ◽  
Health Impacts ◽  
African American Female ◽  
Middle Aged

scholarly journals Validation of connected speech as a marker for cognitive change in late‐middle aged African American adults at risk for Alzheimer's disease

2020 ◽  
Vol 16 (S6) ◽  
Author(s):  
Kimberly D. Mueller ◽  
Elizabeth M. Evans ◽  
Sheryl L. Coley ◽  
Rebecca L. Koscik ◽  
Nia Norris ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
African American ◽  
Cognitive Change ◽  
Middle Aged ◽  
Connected Speech ◽  
African American Adults

scholarly journals P2-598: SUBJECTIVE AND BIOLOGICAL MARKERS OF STRESS IN MIDDLE-AGED CAUCASIAN AND AFRICAN AMERICAN ALZHEIMER'S DISEASE FAMILIES

2019 ◽  
Vol 15 ◽  
pp. P853-P853
Author(s):  
Hanfeng Huang ◽  
William T. Hu ◽  
Liping Zhao ◽  
Ryan Shin ◽  
Danielle D. Verble ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
African American ◽  
Biological Markers ◽  
Middle Aged ◽  
And Biological Markers

Fluoxetine Protects against Dendritic Spine Loss in Middle-aged APPswe/PSEN1dE9 Double Transgenic Alzheimer’s Disease Mice

2020 ◽  
Vol 17 (1) ◽  
pp. 93-103 ◽  
Author(s):  
Jing Ma ◽  
Yuan Gao ◽  
Wei Tang ◽  
Wei Huang ◽  
Yong Tang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dendritic Spines ◽  
Dendritic Spine ◽  
Early Stage ◽  
Learning Ability ◽  
Middle Aged ◽  
Protein Levels ◽  
Spine Pathology ◽  
The Impact

Background: Studies have suggested that cognitive impairment in Alzheimer’s disease (AD) is associated with dendritic spine loss, especially in the hippocampus. Fluoxetine (FLX) has been shown to improve cognition in the early stage of AD and to be associated with diminishing synapse degeneration in the hippocampus. However, little is known about whether FLX affects the pathogenesis of AD in the middle-tolate stage and whether its effects are correlated with the amelioration of hippocampal dendritic dysfunction. Previously, it has been observed that FLX improves the spatial learning ability of middleaged APP/PS1 mice. Objective: In the present study, we further characterized the impact of FLX on dendritic spines in the hippocampus of middle-aged APP/PS1 mice. Results: It has been found that the numbers of dendritic spines in dentate gyrus (DG), CA1 and CA2/3 of hippocampus were significantly increased by FLX. Meanwhile, FLX effectively attenuated hyperphosphorylation of tau at Ser396 and elevated protein levels of postsynaptic density 95 (PSD-95) and synapsin-1 (SYN-1) in the hippocampus. Conclusion: These results indicated that the enhanced learning ability observed in FLX-treated middle-aged APP/PS1 mice might be associated with remarkable mitigation of hippocampal dendritic spine pathology by FLX and suggested that FLX might be explored as a new strategy for therapy of AD in the middle-to-late stage.

P2-027: TARGET ENGAGEMENT IN A PHASE II CLINICAL TRIAL OF AAV2-NGF GENE THERAPY FOR ALZHEIMER'S DISEASE

2006 ◽  
Vol 14 (7S_Part_12) ◽  
pp. P677-P677
Author(s):  
Michael J. Castle ◽  
Fernando Calvo Baltanas ◽  
Imre Kovacs ◽  
Alan H. Nagahara ◽  
Krystof S. Bankiewicz ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trial ◽  
Gene Therapy ◽  
Phase Ii ◽  
Phase Ii Clinical Trial ◽  
Target Engagement ◽  
Ngf Gene
Sign in / Sign up

Export Citation Format

Share Document